Bloomberg reports the obesity drug market is expected to reach as much as $130 billion in annual sales by 2030.

Explore the most expensive construction projects in Chicago in 2024, including the $358 million AbbVie Foundation Cancer Pavilion at the University of Chicago and Related Midwest’s $291 million 400 ...

AbbVie has signed a licensing deal with Gubra A/S to develop an obesity drug, marking the North Chicago company's first foray ...

While Humira’s 2023 loss of exclusivity hung over AbbVie’s head for years, the ascent of the Chicago drugmaker’s immunology successors Skyrizi and Rinvoq under prior CEO Richard Gonzalez has swiftl | ...

Under terms of the deal, Gubra will receive an initial $350 million payment and could earn up to $1.875 billion more in ...

Tenpoint Therapeutics has tasked Carol Kearney with cracking a market that confounded AbbVie. As the biotech’s newly ...

AbbVie (NYSE:ABBV) recently announced the availability of its drug SKYRIZI® in Canada for treating adults with ulcerative ...

North Chicago, Illinois Tuesday, March 4, 2025, 10:00 Hrs [IST] ...